The effects of aldosterone on diet-induced fatty liver formation in male C57BL/6 mice: Comparison of adrenalectomy and mineralocorticoid receptor blocker

European Journal of Gastroenterology and Hepatology

Volumn 25, Issue 9, 2013, Pages 1086-1092

  Gamliel Lazarovich, Aviva ^a   Raz Pasteur, Ayelet ^b   Coleman, Raymond ^a   Keidar, Shlomo ^a,b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

Author keywords

aldosterone; diabetes; eplerenone; fatty liver; metabolic syndrome; mineralocorticoid recepto

Indexed keywords

ALDOSTERONE; EPLERENONE; GLUCOSE; INSULIN; OLEIC ACID; SPIRONOLACTONE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADRENALECTOMY; ALDOSTERONE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; FATTY LIVER; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; IN VITRO STUDY; INSULIN BLOOD LEVEL; INSULIN RESPONSE; INTERMETHOD COMPARISON; LIPID DIET; LIPID STORAGE; LIVER CELL; MALE; METABOLIC SYNDROME X; MOUSE; NONHUMAN; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

ADRENALECTOMY; ALDOSTERONE; ANIMALS; BLOOD GLUCOSE; BLOOD PRESSURE; CELLS, CULTURED; CHOLESTEROL; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; FATTY LIVER; HEPATOCYTES; INSULIN; INSULIN RESISTANCE; LIPOPROTEINS, VLDL; LIVER; MALE; METABOLIC SYNDROME X; MICE; MICE, INBRED C57BL; MINERALOCORTICOID RECEPTOR ANTAGONISTS; OLEIC ACID; SPIRONOLACTONE; TRIGLYCERIDES; WEIGHT GAIN;

EID: 84881375360     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e328360554a     Document Type: Article

References (26)

1. Utzschneider KM, Kahn SE. Review: the role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2006; 91:4753-4761. (Pubitemid 44917301)
2. Kumashiro N, Erion DM, Zhang D, Kahn M, Beddow SA, Chu X, et al. Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc Natl Acad Sci USA 2011; 108:16381-16385.
3. Conn JW, Knopf RF, Nesbit RM. Clinical characteristics of primary aldosteronism from an analysis of 145 cases. Am J Surg 1964; 107:159-172.
4. Tirosh A, Garg R, Adler GK. Mineralocorticoid receptor antagonists and the metabolic syndrome. Curr Hypertens Rep 2010; 12:252-257.
5. Homma T, Fujisawa M, Arai K, Ishii M, Sada T, Ikeda M. Spironolactone but not eplerenone, impairs glucose tolerance in a rat model of metabolic syndrome. J Vet Med Sci 2012; 74:1015-1022.
6. Chapman N, Dobson J,Wilson S, Dahlö f B, Sever PS,Wedel H, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007; 49:839-845. (Pubitemid 351664214)
7. Guo C, Ricchiuti V, Lian BQ, Yao TM, Coutinho P, Romero JR, et al. Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation 2008; 117:2253-2261.
8. Joffe HV, Kwong RY, Gerhard-Herman MD, Rice C, Feldman K, Adler GK. Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus. J Clin Endocrinol Metab 2007; 92:2552-2558. (Pubitemid 47037357)
9. Pessôa BS, Peixoto EB, Papadimitriou A, Lopes de Faria JM, Lopes de Faria JB. Spironolactone improves nephropathy by enhancing glucose-6-phosphate dehydrogenase activity and reducing oxidative stress in diabetic hypertensive rat. J Renin Angiotensin Aldosterone Syst 2012; 13:56-66.
10. Sakata A, Mogi M, Iwanami J, Tsukuda K, Min LJ, Jing F, et al. Improvement of cognitive impairment in female type 2 diabetes mellitus mice by spironolactone. J Renin Angiotensin Aldosterone Syst 2012; 13:84-90.
11. Hirata A, Maeda N, Hiuge A, Hibuse T, Fujita K, Okada T, et al. Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice. Cardiovasc Res 2009; 84:164-172.
12. Wada T, Kenmochi H, Miyashita Y, Sasaki M, Ojima M, Sasahara M, et al. Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet. Endocrinology 2010; 151:2040-2049.
13. Seglen PO. Preparation of isolated rat liver cells. Methods Cell Biol 1976; 13:29-83.
14. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 2005; 11:183-190. (Pubitemid 40321354)
15. Denker PS, Pollock VE. Fasting serum insulin levels in essential hypertension. A meta-analysis. Arch Intern Med 1992; 152:1649-1651.
16. Landin K, Tengborn L, Smith U. Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors. J Intern Med 1991; 229:181-187.
17. Grassi G, Seravalle G, Dell'Oro R, Trevano FQ, Bombelli M, Scopelliti F, et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens 2003; 21:1761-1769. (Pubitemid 37076361)
18. Hales CN, Milner RD. The role of sodium and potassium in insulin secretion from rabbit pancreas. J Physiol 1968; 194:725-743.
19. Mokuda O, Sakamoto Y. Sodium at high concentrations increases glucoseinduced insulin secretion in the perfused rat pancreas. Acta Diabetol 1998; 35:154-157. (Pubitemid 28505229)
20. Naeser P. Effects of adrenalectomy on the obese-hyperglycemic syndrome in mice (gene symbol ob). Diabetologia 1973; 9:376-379.
21. Makimura H, Mizuno TM, Roberts J, Silverstein J, Beasley J, Mobbs CV. Adrenalectomy reverses obese phenotype and restores hypothalamic melanocortin tone in leptin-deficient ob/ob mice. Diabetes 2000; 49:1917-1923.
22. Strauch B,Widimský J, Sindelka G, Skrha J. Does the treatment of primary hyperaldosteronism influence glucose tolerance? Physiol Res 2003; 52:503-506. (Pubitemid 37039916)
23. Dubuc PU,Wilden NJ. Adrenalectomy reduces but does not reverse obesity in ob/ob mice. Int J Obes 1986; 10:91-98. (Pubitemid 16042424)
24. Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis 2010; 28:155-161.
25. Kim HJ, Kim HJ, Lee KE, Kim DJ, Kim SK, Ahn CW, et al. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch Intern Med 2004; 164:2169-2175.
26. Caprio M, Antelmi A, Chetrite G, Muscat A, Mammi C, Marzolla V, et al. Antiadipogenic effects of the mineralocorticoid receptor antagonist drospirenone: potential implications for the treatment of metabolic syndrome. Endocrinology 2011; 152:113-125.